The FDA designated 166 products under its breakthrough devices program in its most recent financial year, reversing the ...

This is the first gene therapy for AADC deficiency to receive US regulatory approval and the first that can be administered directly to the brain.

Aurinia Pharmaceuticals Reports Q3 and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development ...